TOUJEO MAX SOLOSTAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOUJEO MAX SOLOSTAR (TOUJEO MAX SOLOSTAR).
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action. It binds to the insulin receptor, activating downstream signaling pathways to promote glucose uptake in peripheral tissues, inhibit hepatic gluconeogenesis, and suppress lipolysis and proteolysis.
| Metabolism | Insulin glargine is partially metabolized at the injection site and in the circulation. The primary metabolic pathway involves cleavage of the C-terminal of the B chain to form two active metabolites: M1 (A21-Gly-insulin) and M2 (A21-Gly-des-B30-Thr-insulin). |
| Excretion | Degraded by insulin-degrading enzyme; minimal renal excretion (<1% unchanged). Biliary/fecal elimination accounts for the remainder. |
| Half-life | Terminal elimination half-life of 19 hours (range 16-21 h) in steady state, reflecting prolonged insulin glargine absorption from the subcutaneous depot. |
| Protein binding | Approximately 90% bound to albumin and alpha-2-macroglobulin. |
| Volume of Distribution | 0.04–0.05 L/kg (low, primarily confined to plasma and interstitial fluid, reflecting high protein binding and molecular size). |
| Bioavailability | Subcutaneous injection: approximately 100% (absolute bioavailability; insulin glargine is completely absorbed from the subcutaneous depot). |
| Onset of Action | Subcutaneous injection: 6 hours (onset of metabolic effect, slower than standard glargine U-100 due to higher concentration and larger injection volume). |
| Duration of Action | Greater than 24 hours (up to 36 h) with a flat, peakless profile; suitable for once-daily dosing at any time, but same time daily recommended. |
Subcutaneous injection once daily at the same time every day. Starting dose for patients with type 2 diabetes: 0.2 units/kg or 10 units once daily, titrated based on fasting plasma glucose. Maximum dose per injection: 160 units (2 mL) or 300 units (3 mL) depending on prefilled pen.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-89 mL/min: No dose adjustment required but monitor glucose more frequently. GFR <30 mL/min: Consider dose reduction due to increased risk of hypoglycemia; start with lower doses and titrate cautiously. |
| Liver impairment | Child-Pugh Class A or B: No dose adjustment but monitor glucose closely. Child-Pugh Class C: Consider dose reduction due to impaired gluconeogenesis; start at lower doses and titrate cautiously. |
| Pediatric use | Not approved for patients <18 years of age due to lack of safety and efficacy data. For adolescents ≥18 years, dosing follows adult guidelines. |
| Geriatric use | Initiate at 0.2 units/kg or 10 units once daily. Use lower starting doses (e.g., 10 units) and titrate slowly (e.g., every 3-4 days) to minimize hypoglycemia risk. Monitor renal function and adjust accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TOUJEO MAX SOLOSTAR (TOUJEO MAX SOLOSTAR).
| Breastfeeding | Insulin glargine is a large molecule (6063 Da) that is unlikely to be excreted into breast milk in significant amounts. No specific M/P ratio has been reported. It is considered compatible with breastfeeding because oral bioavailability in infants is minimal, and insulin is normally present in human milk at low levels. However, caution is advised to monitor for signs of hypoglycemia in the breastfeeding infant, especially if high doses are used. |
| Teratogenic Risk | Insulin glargine does not cross the placenta significantly. No teratogenic effects have been observed in animal studies, and human data do not indicate an increased risk of major malformations. However, uncontrolled maternal diabetes, including hyperglycemia and hypoglycemia, poses risks to the fetus in all trimesters. First trimester: poor glycemic control is associated with increased risk of congenital anomalies. Second and third trimesters: hyperglycemia is associated with macrosomia, neonatal hypoglycemia, and respiratory distress syndrome. Hypoglycemia can occur in the mother due to intensified glycemic control. |
■ FDA Black Box Warning
Not applicable; no black box warning.
| Serious Effects |
["Hypersensitivity to insulin glargine or any excipients","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia is the most common adverse reaction and may be life-threatening","Accidental mix-ups between insulin products can occur; do not transfer insulin into syringes","Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia","Hypokalemia may occur; monitor potassium levels in patients at risk","Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs)","Monitor for signs of injection site reactions and lipodystrophy","Use with caution in patients with renal or hepatic impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose levels frequently (including fasting, pre-meal, and postprandial) to optimize glycemic control. Assess HbA1c every 1-2 months. During labor and delivery, monitor maternal blood glucose every 1-2 hours to prevent maternal hypoglycemia and neonatal hypoglycemia. Fetal monitoring: ultrasound for growth, anatomy, and amniotic fluid index; nonstress test and biophysical profile in third trimester. Monitor for signs of macrosomia and polyhydramnios. In the neonate, monitor blood glucose levels for at least 24-48 hours after birth. |
| Fertility Effects | Insulin glargine is not known to have direct adverse effects on fertility. In animal studies, no impairment of fertility was observed. In humans, uncontrolled diabetes (including hyperglycemia and hypoglycemia) can impair fertility in both men and women. Achieving good glycemic control with insulin therapy, including glargine, may improve fertility outcomes. |